Literature DB >> 2936583

Oral treatment of Pseudomonas-induced urinary tract infections with ciprofloxacin.

H Van Poppel, M Wegge, H Dammekens, V Chysky.   

Abstract

In an open study, a group of 11 patients with asymptomatic urinary tract infections, caused by resistant Pseudomonas strains, were given 200 mg of ciprofloxacin per day for 1 week. All strains displayed an in vitro sensitivity to the drug. Complete clinical resolution was obtained in 8 patients and long-term eradication in 3. No adverse reactions and only minor and reversible laboratory changes were recorded. Ciprofloxacin could be a valuable oral drug in the treatment of severe urinary infections. However, more clinical studies on the development of resistance under therapy and with other dose schedules are indicated.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2936583     DOI: 10.1159/000238392

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  5 in total

1.  Comparison of three dosage regimens of ciprofloxacin in urinary tract infections.

Authors:  V Prát; M Horcicková; K Matousovic; M Hatala
Journal:  Int Urol Nephrol       Date:  1990       Impact factor: 2.370

Review 2.  Clinical experience with ciprofloxacin in the treatment of urinary tract infections: a review.

Authors:  H van Poppel; V Chyský; R Hullmann; L Baert
Journal:  Infection       Date:  1988       Impact factor: 3.553

Review 3.  Overview of clinical experience with ciprofloxacin.

Authors:  A P Ball
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

Review 4.  Quinolone resistance in Pseudomonas aeruginosa and Staphylococcus aureus. Development during therapy and clinical significance.

Authors:  A Dalhoff
Journal:  Infection       Date:  1994       Impact factor: 3.553

Review 5.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.